Sensitivity-based analytical approaches to support human absolute bioavailability studies.

The characterization of absolute bioavailability (BA) is useful for non-intravenous (iv.) formulations during drug development and is required by some health authorities. A study design of co-administrating an iv. isotopically labeled microdose with a therapeutic oral dose is a viable approach for the determination of human PK and has been accepted by regulatory agencies. The implementation of an iv.-microdose with oral therapeutic dose in absolute BA studies speeds up clinical development. In recent years, AMS to measure a radiolabeled microdose has been utilized to support several clinical absolute BA studies. An alternative approach for conducting microdose studies is using LC-MS/MS alone to quantitate both the iv. drug and the oral drug. Because both labeled and unlabeled drugs can be measured simultaneously with LC-MS/MS, it is cost effective. However, for compounds with high volume of distribution and/or poor LC-MS/MS response, AMS still provides a superior LLOQ. In this Perspective, we discuss a paradigm for selecting either an LC-MS/MS or AMS-based approach for generating concentration data in absolute BA studies dependent on the required sensitivity.

[1]  A. Arjomand,et al.  Simultaneous AMS determination of 14C content and total carbon mass in biological samples , 2010 .

[2]  Jim X. Shen,et al.  Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS. , 2012, Bioanalysis.

[3]  W. Humphreys,et al.  Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  A. Arjomand,et al.  Performance Evaluation of the New AMS System at Accium BioSciences , 2007, Radiocarbon.

[5]  J. Vogel,et al.  Analytical validation of accelerator mass spectrometry for pharmaceutical development. , 2010, Bioanalysis.

[6]  R. Colin Garner,et al.  The utility of microdosing over the past 5 years , 2008, Expert opinion on drug metabolism & toxicology.

[7]  M. Salehpour,et al.  Biological accelerator mass spectrometry at Uppsala University. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[8]  Hao Jiang,et al.  Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. , 2012, Analytical chemistry.

[9]  F. LaCreta,et al.  When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies. , 2012, Bioanalysis.

[10]  K. Stenström,et al.  A guide to radiocarbon units and calculations , 2011 .

[11]  Hai‐Yan Xie,et al.  A mild and reliable method to label enveloped virus with quantum dots by copper-free click chemistry. , 2012, Analytical chemistry.

[12]  F. LaCreta,et al.  Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. , 2013, British journal of clinical pharmacology.

[13]  M. Suter,et al.  MICADAS: A new compact radiocarbon AMS system , 2007 .

[14]  W. Humphreys,et al.  Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections , 2009, Drug Metabolism and Disposition.